New device offers a convenient way to monitor compressed air for viable particles
New SAS Super Pinocchio CR available from Cherwell Laboratories.
Specialist cleanroom microbiology solutions company offers the new SAS Super Pinocchio CR compressed air sampling device.
Cherwell Laboratories has augmented its range of microbial air samplers with the addition of the SAS Super Pinocchio CR. This new air sampling device offers a more convenient way to monitor for viable particles in compressed air and other gas supplies used in controlled environments.
This updated version of the Pinocchio II compressed air sampling device can be fully dismantled for easy cleaning and decontamination — a process made more simple and effective by the device being manufactured in stainless-steel.
The Pinocchio CR provides a controlled method for bioburden monitoring of compressed air and other gases and can be included in an environmental monitoring program. It is ideal for use in manufacturing facilities where compressed air monitoring is falling under increasing regulatory scrutiny.
To ensure continuity with other environmental monitoring programs, the Pinocchio CR uses the same method of active air sampling as the rest of the SAS range of portable units. Using the multipoint impaction method of active sampling, air is aspirated through a perforated cover (a sampling head) and any particles present are impacted on to the agar surface of a contact plate or 90-mm Petri dish for subsequent culture.
This totally portable system, which is now more compact than the current Pinocchio II, does not require power and, therefore, can be used in high risk areas. Set up is simple as the Pinocchio CR is easily attached to an air or gas line, and a regulating valve controls the pressure delivered to the sampler. Airflow from the compressed supply is regulated through a flow meter before passing through its traditional SAS sampling head, with the unit capable of sampling 100 L/min.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.